Genetic manipulation of the adenovirus type 5 represents one strategy to modify viral transduction properties in vitro and in vivo. In the majority of studies to date, reporter gene activity has been monitored to assess transduction efficiency. BRCA1 is a gene whose protein product is clinically important, biologically toxic, difficult to overexpress, and difficult to detect as an untagged protein species. Thus, it represents an attractive candidate from which to evaluate the efficacy of a gene delivery system. In the present study, transgene expression was assessed employing otherwise isogenic viruses, which differed only in the presence or absence of an RGD integrin-binding motif in the HI loop of the Ad fiber knob. We utilized a combination of BRCA1 expression level comparisons among several human BRCA1/mutant BRCA1/murine Brca1 constructs and reporter gene activity following transduction of a panel of human breast and ovarian tumor cell lines representative of both sporadic and hereditary cases. A general overall concordance in efficiency was observed, whether the biological readout measured was reporter gene activity or steady-state level of ectopic BRCA1 protein produced. Importantly, the expression of full-length wild-type BRCA1 protein, clinically relevant mutant BRCA1 proteins or murine Brca1 was superior when the gene was delivered via the RGD-modified Ad. The ectopic BRCA1 stabilized endogenous BARD1 and this functional effect was evident at lower input viral doses when BRCA1 was delivered via the RGD-modified Ad. Quantitative, noninvasive, real-time image analysis of reporter gene function in nude mice harboring human ovarian tumor xenographs demonstrated a similar enhancement of expression in vivo by the RGD fiber modification, with low levels of transduction of normal mouse mesothelium. These results provide additional evidence supporting the concept that rational modification of viral vectors can result in the delivery of functionally active therapeutic proteins such as BRCA1 that present with technical difficulties with regard to their expression.
fficient infection of target cells by adenoviral (Ad) 5 vectors requires two predominant viral-host cell receptor interactions. Primary adsorption of Ad relies on the interaction of the knob domain of the viral fiber protein with a cell surface receptor designated coxsackievirus and adenovirus receptor (CAR). [1] [2] [3] Subsequently, the interaction of the viral penton base with a V integrins facilitates the entry of Ad via clathrin-mediated endocytosis. 4, 5 Ad have a broad host range because of the widespread presence of CAR; however, gene delivery to a specific target cell in the context of cancer gene therapy is often precluded by both the ubiquitous nature of CAR expression on nontumor cells 2, 3, [6] [7] [8] and also the frequent loss of CAR expression in tumors. 7, [9] [10] [11] [12] [13] [14] Direct manipulation of the initial viral-target cell interaction by genetic modification of individual viral coat proteins, including the fiber, 9, 11, [15] [16] [17] [18] [19] hexon, 20 penton, 21 and pIX 22 have been utilized as a means to overcome tropism limitations associated with first-generation Ad vectors. Simultaneous genetic manipulation of both the Ad fiber and penton base 23 and fiber shaft and knob in combination 24 has also been reported. In the majority of these studies, reporter genes such as b-galactosidase (b-gal) 15, 16, 20 or luciferase (luc) 9, 17, 18, [22] [23] [24] have been utilized as the inserted gene from which to monitor efficiency, although additional studies have also utilized therapeutic genes. [25] [26] [27] [28] While the use of reporter genes provides a convenient method for quantitative assessment of transduction efficiency, the demonstration of benefits derived from genetic modification of the Ad vector in the context of clinically relevant genes or involving the utilization of genes whose protein products are otherwise difficult to express or detect should provide an additional complementary, stringent, and directly applicable test of vector efficiency. BRCA1 is a B220 kDa nuclear phosphoprotein implicated in a wide range of cellular activities including the response to DNA damage, transcriptional regulation, ubiquitination, growth arrest, and apoptosis. 29 In our experience, expression and detection of untagged, ectopic BRCA1, BRCA1 missense or C-terminal truncation mutants is technically difficult using traditional plasmid and retroviral vector platforms. In addition, we have also been unable to establish a regulated expression system in BRCA1 null breast or ovarian tumor cell lines that have been established from BRCA1 mutation carriers, although we (Riet van der Meer and RAJ, unpublished), like others, 30, 31 have succeeded in the creation of this type of system in nonbreast, nonovarian cell lines (HEK 293, U2OS). The reasons for the difficulties associated with BRCA1 protein expression and detection are not understood. In addition to anti-BRCA1 antibody specificity/ sensitivity issues, 32, 33 the poor expression of BRCA1 may be related to the large size of BRCA1 protein, 34 BRCA1-associated biological toxicity [35] [36] [37] [38] accompanied by the induction of apoptosis in some settings, 31, 39, 40 inefficient translatability of the BRCA1 mRNA, 31, 41, 42 and intracellular regulation of BRCA1 protein levels 43, 44 including BRCA1-associated autoubiquitination. 45 We 37, 38, 46 have previously reported on the use of first-generation (E1/E3-deleted) Ad vectors as a method to overcome the poor protein expression associated with BRCA1 plasmid constructs and to introduce functional wild-type human BRCA1, disease-associated human BRCA1 mutants, murine Brca1 or murine Brca1 mutant proteins into a variety of breast and ovarian cell lines in vitro. This approach allowed for robust BRCA1 expression and unambiguous detection of these proteins in a variety of cell lines and model systems of interest including primary mouse embryo fibroblasts (MEF) and primary human mammary epithelial cells (HMECs). 38 As we continue to explore the use of BRCA1 gene replacement therapy as an experimental treatment for advanced ovarian cancer, 47, 48 we have modified the Ad backbone of these vectors by incorporating the RGD-4C peptide 49 into the HI loop of the Ad fiber knob as pioneered by Curiel and coworkers. 9 This advanced-generation Ad vector was constructed using an Ad fiber shuttle vector in combination with a popular simplified procedure for the generation of recombinant Ad vectors. 50 These manipulations allow for the RGD-fiber modification to be incorporated into any recombinant Ad of interest using the basic Ad Easy protocol. Moreover, our simple procedure used to create the RGD-4C fiber modification can be adapted to incorporate any tolerable targeting motif of choice to modify Ad fibers at the HI loop domain for subsequent use in the Ad Easy protocol. Using several model systems currently employed in the BRCA1 field, we compared the ectopic expression levels of wild-type human BRCA1, murine Brca1, and several disease-associated human BRCA1 mutants produced using a first-generation Ad 5 vector containing a native fiber against that produced when the same genes were delivered by an isogenic virus containing the RGD-fiber modification. Semiquantitative measurements of BRCA1 protein produced by these vectors were compared with results obtained from a similar analysis using the more standard approach of reporter gene activity. These results provide additional examples supporting the potential benefits of genetic modification of the Ad vectors, but in the context of expression of a clinically relevant gene that presents with technical challenges in terms of its expression.
Materials and methods

Cell lines
HCC1937
51
(hereditary breast carcinoma), MCF-7 (sporadic breast carcinoma) and SK-OV-3 (sporadic ovarian carcinoma), cell lines were obtained from the ATCC (Manassas, VA), and SNU-251 52 (hereditary ovarian carcinoma) were obtained from the Korean Cell Line Bank (Seoul National University, Seoul, Korea). All cells were cultured as recommended by the suppliers.
Flow cytometry
Flow cytometry for cell surface markers was performed as described. 9 The primary antibodies utilized against human integrins were monoclonal antibodies anti-a V b 3 integrin (LM609) and anti-a V b 5 (P1F6) obtained from Chemicon International, Inc (Temecula, CA). Anti-human CAR monoclonal antibody RmcB 53 was obtained from Jeffrey Bergelson (University of Pennslyvania, Philadelphia, PA). FITC-conjugated secondary antibodies were from Santa Cruz Biotechnologies (Santa Cruz, CA). 10,000 cells were counted.
Ad vectors
Construction of first-generation Ad vectors which express human BRCA1, clinically validated BRCA1 mutants, or murine Brca1transgenes has been described. 38 The second-generation Ad vectors were similarly constructed except that the homologous recombination reaction utilized a modified AdEasy-1 vector backbone 50 that contained the RGD-4C peptide 49 incorporated into the HI loop of the Ad fiber knob. 9 This plasmid was designated pAdEasy-1 (RGD) and was constructed utilizing a 6 kb EcoRI-BamHI fragment from pAdEasy-1, which contains the Ad fiber knob coding sequence. This fragment was cloned into pBluescript and a CCA codon, which encodes proline 547 in the Ad fiber knob protein HI loop turning point, was deleted by site-directed mutagenesis. 38, 50 Transduction, reporter gene, protein, and RNA expression analysis Ad-mediated gene transfer was performed as previously described. 38 The range of multiplicity of infection (moi; viral particles (VPs) per cell) utilized is listed in each figure. In situ b-galactosidase activity was measured using X-gal as a substrate. Quantitative b-galactosidase activity was measured using a chemiluminesence b-galactosidase kit (Galacto-light, Tropix, Bedford, MA) following the manufacturer's instructions. Western blotting was conducted as previously described. 38 The antibodies used for BRCA1 protein detection were Ab-1 (Oncogene Research Products, Boston, MA) or C-20 (Santa Cruz). The antibody used to detect BARD1 was rabbit anti-BARD1 (59F) obtained from Richard Baer (Columbia University, New York, NY). Secondary antibodies were from Santa Cruz and Jackson ImmunoResearch Laboratories, Inc. (West Grove, PA). Detection was accomplished by enhanced chemiluminesence. Northern blotting was done as previously described using 20 mg of total RNA per lane. 38 The probe used to detect murine Brca1 was a 1.9 kb HindIII fragment from pcBrca1 (MC, unpublished). The GAPDH probe was obtained from Ambion (Austin, TX). Northern blots were quantified using an autoradiography system (Cyclone storage phosphor system, Packard Instrument Company, Meriden, CT).
In vivo image analysis
In vivo, noninvasive imaging in live mice was performed as described. 54 Briefly, female nude mice (NU/Jfoxn1(nu)) (Jackson Laboratories, Bar Harbor, ME) were injected intraperitonally (i.p.) with a 500 ml volume containing 1 Â 10 6 SK-OV-3 tumor cells. Using this inoculum, there was 100% tumor establishment in these mice (MC, RAJ and JT Holt, unpublished observations). Approximately 45-60 days postinjection, the mice develop ascites, carcinomatosis, and cachexia, ultimately progressing to death. At 48 h prior to imaging, the mice were injected i.p. with 500 ml of PBS containing 1 Â 10 10 VPs of either AdLuc or AdRGDLuc. On the day of imaging, the mice were injected i.p. with 500 ml of a solution of 1 mg/ml K + d-Luciferin (Biosynth International, Naperville, IL). 5 minutes after substrate injection, the mice were anesthetized with isoflurane (Aerrane, Baxter Healthcare Corporation, Deerfield, IL) and placed on a focusing stage within a light-tight macroimaging box. Whole mouse luminescence was imaged at various time points following substrate injection using a photon-counting intensified CCD (ICCD) camera (Hamamatsu C2400-35) coupled with a Nikkor 50 mm f/1.2 lens. Nontumor-bearing recipients were similarly treated with Ad vectors 48 h prior to substrate injection and imaging. Images displayed in Figure 5 were captured using a 3 minute exposure. Following luminescence imaging, conventional images were obtained using low-level incandescent lighting to provide orientation of the luciferase-generated emission relative to the mice.
Results
Modification of the AdEasy-1 backbone
The AdEasy system represents a straightforward and versatile approach to generate recombinant Ad vectors. 50 We modified pAdEasy-1 by incorporating the RGD-4C peptide into the HI loop of the Ad fiber knob as previously described by Dmitriev et al 9 creating pAdEasy-1 (RGD). The creation of an Ad fiber shuttle vector, pBS fiber, allowed for the insertion of any targeting motif to be incorporated into the AdEasy-1 backbone using a two-step procedure. In the first step, annealed double-stranded oligonucleotides corresponding to the motif of interest were inserted into the SpeI site of pBS fiber. Secondly, the modified fiber fragment was then cloned back into pAdEasy-1 as an EcoRI-BamHI restriction fragment. The modified AdEasy-1 backbone was then utilized in the basic AdEasy homologous recombination reaction employing the transgene-containing shuttle vector of choice. Rates of successful recombination between AdEasy-1 (RGD) and a variety of transgene-containing shuttle vectors were slightly lower (two-five fold, data not shown) than that obtained with the unmodified AdEasy-1 backbone as measured by supercoiled and restriction endonuclease analysis of Kan R Escherichia coli BJ5183 clones, however, successful recombinants could still be obtained.
CAR and integrin levels on human tumor cell targets
There are two tumor cell lines established from hereditary cancer patients harboring known BRCA1 mutations. Cell line HCC1937 was established from a BRCA1 breast cancer patient 51 and SNU-251 cells were derived from a BRCA1 ovarian cancer patient. 52 Although the precise function that represents the in vivo tumor suppressor activity of BRCA1 remains unclear, these two cell lines currently serve as the available in vitro model systems for BRCA1 functional studies conducted on a BRCA1 mutant background. In addition, we examined one breast (MCF-7) and one ovarian (SK-OV-3) tumor cell line derived from sporadic cases, although the role of BRCA1 in sporadic breast and ovarian cancer cases is also unclear at the present time. 29, 55 MCF-7 cells are hemizygous wild type at the BRCA1 locus, 35 while SK-OV-3 cells have not been genotyped in this regard. Protein lysates prepared from both sporadic cell lines contain endogenous fulllength BRCA1 as judged by p220-240 kDa protein species reactive with a variety of anti-BRCA1 antibodies (Fig 3  and data not shown) . Flow cytometric analysis of CAR Enhanced BRCA1 expression by RGD-modified Ad M Campbell et al and a V b 3 and a V b 5 integrin levels was performed on these cells and results are shown in Figure 1 . The human tumor cell lines under study show a range of levels of both CAR (Fig 1a, b , left panel) and integrins (Fig 1a, b, right panel) ; however, all expressed at least a low level of CAR. MCF-7 cells and SK-OV-3 cells expressed low levels of CAR, while both BRCA1 null cell lines possessed relatively high levels of CAR. Integrin levels were, in general, moderate to high with the exception of SNU-251 cells, which appeared to be negative for expression of a V b 3 and expressed low levels of a V b 5 .
Transduction efficacy assessment using b-galactosidase reporter activity
The four human tumor cell lines under study were transduced with AdGFPLacZ or AdRGDGFPLacZ vectors and assayed by either in situ (Fig 2a) or (Fig 2b) b-galactosidase activity measurements 24 hours post-transduction. Qualitative assessment of the in situ assay in the tumor cell lines (Fig 2a) revealed a shift in the percentage of blue (lacZ+) cells to lower moi using the AdRGD vector relative to the Ad5 vector. Enumeration of the number of blue cells per five highpower fields indicated a B2-10-fold reduction in the moi necessary to achieve a 490% tranduction rate (data not shown). Similarly, the quantitative b-galactosidase assay (Fig 2b) confirmed that the AdRGD vector conferred a 2 to 15-fold relative enhancement of expression over the range of moi tested, depending on the moi compared. The lowest overall degree of relative augmentation imparted by the AdRGD fiber was observed in the SNU-251 cells (1-11-fold), although the range of enhancement in these cells overlaps with that observed in the other cell lines tested, dependent on the moi compared (Fig 2b) .
Transduction efficacy assessment using BRCA1 transgene expression levels
We had previously reported on the use of Ad vectors to overcome technical difficulties encountered with BRCA1 overexpression and as a method to (re-)introduce functional BRCA1 protein into cells. 37, 38, 46 Thus, for our own experimental purposes, we considered ectopic BRCA1 expression levels as a better indicator of vector efficacy than reporter gene activity. Accordingly, we evaluated the expression of wild-type BRCA1, two clinically validated BRCA1 mutants, and murine Brca1 in the context of Ad or AdRGD vectors (Fig 3) . In breast tumor cell lines derived from a hereditary case (HCC1937, Fig 3a) or a sporadic case (MCF-7, Fig 3b) , there was, in general, a reduction in the minimal moi needed to detect BRCA1 protein expression when the RGD-modified Ad was utilized as a vector when compared to the Ad5 backbone (Fig 3a, b top panel, compare lanes 2, 3 versus lanes 7, 8) . Similar results were obtained when two mutant BRCA1 transgenes were monitored (Fig 3a, b , second and third panels). The two BRCA1 mutants that were monitored were a missense mutation that maps to the BRCA1 RING domain located at the N-terminus (BRCA1 C61G) and a truncation mutant that terminates expression in the 5' region of BRCA1 exon 11 (BRCA1 340Stop). RGDmediated augmentation of expression of BRCA1 mutant 1853stop, which lacks the C-terminal 11 amino-acid residues of BRCA1 38 was also observed (data not shown). In addition, in most cases, at viral input levels which result in the generation of an Ad-mediated gene product band on the Western, the level of expression is higher when delivered by the AdRGD vector relative to that produced by Ad5 (Fig 3a, b, compare lanes 2-6 versus  lanes 7-11) . Similar results were obtained in these cell lines when murine Brca1 was the monitored gene. The lack of available antibodies against murine Brca1 precluded its analysis at the protein level; however, we were able to demonstrate an improvement in Brca1 expression mediated by the RGD fiber at the RNA level by Northern analysis (Fig 3a, b, lower two panels) . Quantitation of the Northerns in Figure 3a and b indicated a 3 to 5-fold (HCC1937) and 2 to 8-fold (MCF-7) increase in Brca1 transcript levels, depending on the individual moi compared. Similar to the results obtained in the breast lines, in the SK-OV-3 ovarian tumor cell line established from a sporadic ovarian cancer patient (Fig 3d) , both BRCA1 340Stop protein (Fig 3d  top panel) and murine Brca1 RNA expression (2-8-fold) (Fig 3d, lower two panels) was higher when the gene was delivered via the RGD-modified Ad. The SNU-251 cell line derived from a hereditary ovarian cancer patient exhibited a modest 1.5-fold ( Northern Fig 3c, lower two  panels) to B2.5-fold improvement (Western, Fig 3c, upper three panels) when the RGD-modified Ad was utilized relative to the Ad5 vector. The augmentation of either reporter (Fig 2) or BRCA1 construct (Fig 3) expression mediated by the AdRGD appeared to correlate with the relative proportions of CAR and a V b 3 and a V b 5 integrin levels on the cell surface, in that cells containing a relatively lower level of CAR and moderate to high levels of integrins (MCF-7, Fig 1a; SK-OV-3, Fig  1b) appeared to benefit most from the RGD fiber modification, whereas the degree of augmentation in cells with a relative abundance of CAR (HCC1937, Fig 1a; SNU-251, Fig 1b) and/or low of a V b 3 and a V b 5 integrins (SNU-251, Fig 1b) benefited to a lesser extent.
Enhancement of functional stabilization of endogenous BARD1 by AdRGD-mediated BRCA1
The interaction of BRCA1 with BARD1 is an established interaction between these two proteins 56 utilizing residues mapping to regions that are adjacent to the RING domain present in each partner. 57 The significance of the BARD1-BRCA1 association is not known, but this interaction results in stabilization of each protein partner in the heterodimer, 58 enhances BRCA1 nuclear retention and BRCA1 foci formation, 59 and stimulates the ubiquitin (E3)-ligase activity associated with the RING domain of BRCA1. 45, 58, 60, 61 The interaction between Admediated BRCA1 and endogenous BARD1 was utilized as a measure of functional activity of ectopic BRCA1. This activity was assessed by Western analysis of endogenous BARD1 levels in lysates prepared from AdBRCA1-or AdRGDBRCA1-transduced cells. The steady-state level of endogenous BARD1 protein was increased at lower moi when BRCA1 was delivered via AdRGD relative to the Ad5 vector in cell lines derived from either hereditary (Fig 4a) or sporadic (Fig 4b) breast tumor cell lines (compare Fig 4a or b, lane 1 against lanes  2-5 versus lanes 6-9) . These data provide one indication that higher levels of functionally active ectopic BRCA1 were produced as a result of transduction with the AdRGD relative to the Ad5 vector. AdLuc (Fig 4a, b , lane 10) or AdRGDLuc (Fig 4a, b, lane 11 ) transduction of either cell line (moi 10
3 ) did not result in the stabilization of BARD1 confirming the specificity of the Ad-mediated interaction. Consistent with the BRCA1 expression study presented in Figure 3c , SNU-251 cells showed no relative enhancement of BARD1 stabilization because of the RGD-fiber modification when the two Where error bars are not seen, the error was too small to be seen on the graph. 
BRCA1 Ad vectors were compared (data not shown).
Northern analysis revealed similar levels of endogenous BARD1 mRNA levels in the HCC1937 and MCF-7 transductants, confirming that the observed effect is posttranscriptional (data not shown).
Real-time, noninvasive in vivo analysis of AdRGDmediated expression enhancement
We are currently constructing Ad vectors designed to express both a reporter gene (luciferase) and BRCA1 or mutant BRCA1 in a bicistronic arrangement. We anticipate that this type of Ad vector will allow real-time, noninvasive, in vivo image analysis of locoregional BRCA1 gene therapy for ovarian cancer in a preclinical mouse model. Our goal is to simultaneously image tumor cell burden using GFP-expressing tumor cells (fluorescence) in combination with luciferase activity (luminescence) as a marker for vector distribution and as a surrogate marker for BRCA1 expression. 54, 62 As a prelude to this type of analysis, we have compared luminescence intensities in vivo using tumor-bearing nude mice treated with luciferase expressing Ad vectors comparing the Ad5 versus AdRGD backbone. Nontumor-bearing recipients were similarly treated with either of the two vectors in order to ascertain transduction rates of each vector towards normal mouse mesothelium. As shown in the image analysis (Fig 5, lower four panels) , the RGD-fiber modification enhanced luciferase activity in vivo in living animals presenting with advanced SK-OV-3 i.p. tumors by 5-fold (Fig 5 tumor) . Similar treatment of nontumor-bearing animals (Fig 5, control) resulted in background (Adluc) or extremely low (AdRGDluc) intensity signals relative to that generated by the tumorbearing animals. Conventional (white light) images were obtained to provide orientation of the bioluminescence Enhanced BRCA1 expression by RGD-modified Ad M Campbell et al images relative to the mice (Fig 5, upper four panels) . Similar results were obtained when bioluminescence images were captured using tumor-bearing nude mice harboring subcutaneous implanted tumors that presented with nodular tumor formation, although in these cases luciferase activity was localized to discrete tumor nodules (data not shown).
Discussion
In this report, we have genetically modified the Ad fiber knob as previously pioneered by Curiel and co-workers 9 by inserting the RGD-4C peptide into the backbone of the popular Ad Easy system of He et al. 50 In the construction of this targeted Ad, we generated a fiber shuttle vector that allows for the insertion of sequences corresponding to any targeting motif of interest to be incorporated into the Ad fiber HI loop in the context of the basic AdEasy procedure. The targeting motif is simply inserted as a double-stranded oligonucleotide into the SpeI site of pBS fiber. Following sequence verification of this intermediate, the modified fiber is then cloned back into the AdEasy-1 backbone. The Ad backbone that contains the fiber-modification is then utilized in the AdEasy protocol. This simple procedure should facilitate the construction of fiber modified Ad vectors beyond the example of the RGD-4C peptide motif described herein.
The RGD-4C fiber modification has been subject to extensive experimental evaluation in the context of numerous gene therapy applications 25, 27, 28, [63] [64] [65] [66] [67] [68] [69] [70] [71] and has been reported to augment transduction rates and expression of reporter genes up to three orders of magnitude relative to an isogenic first-generation Ad with a native fiber. 9, 13, 67 Other reported degrees of transductional augmentation mediated by Ad-RGD are somewhat more modest, 27, 63, 64, 66, 72 and consistent with our results. We note that all of the tumor cell lines we targeted in this paper express some level of CAR (Fig 1) , and thus may not be as stringent as primary tumor cells 9, 72, 73 in terms of target test material. Our choice of these cell lines for our studies was dictated by our interest in BRCA1. We compared the in vitro efficacy gain mediated by this fiber modification using both reporter gene activity (Figs 2, 5 ) and the expression level of functional BRCA1 constructs (Figs 3, 4) . Using either means of evaluation, there was a general agreement between the two methods, although there are slight numerical differences apparent in the relative levels of augmentation dependent on both the gene monitored (reporter, BRCA1, mutant BRCA1, murine Brca1) and its method of assessment (in situ or quantitative b-galactosidase activity, Western or Northern). Although we have not measured ectopic BRCA1 protein in vivo, noninvasive, real-time imaging of tumorbearing and Ad-transduced nude mice demonstrated a similar degree of enhancement of reporter gene expression with background levels of transduction of the normal mouse mesothelium. A small RGD-mediated augmentation of transduction to the normal mouse mesothelium was evident (Fig 5, control) ; however, this level of transduction was much lower than that seen in the ovarian cancer cells. A slight increase in RGD-mediated gene transfer to human mesothelial tissue has been previously reported. 72 While we have utilized a reporter gene approach (Figs 2, 5) we considered BRCA1 expression and functional activity (Figs 3, 4) as a better indicator of efficacy for our experimental purposes. The level of enhancement of BRCA1/mutant BRCA1 protein expression afforded by the RGD-fiber modification appears to be in the range of B2 to Br10-fold, depending on the target tumor cell line (Fig 3) . This is consistent with the results of quantitative assessment of the Brca1 Northern data (Fig 3) , which range from o2-fold (SNU-251) to B3 to 5-fold (HCC1937) to 2 to 8-fold (MCF-7 and SK-OV-3), depending on the moi one compares between the two vectors. The ectopic BRCA1 produced appeared to be functional as judged by its ability to stabilize endogenous BARD1 (Fig 4) . Using endogenous BARD1 levels as an indicator for functional BRCA1 expression, enhancement of expression by the RGD fiber is also supported by the results in the two breast lines examined (Fig 4) . A reduction in the moi needed to retard clonal outgrowth among transduced tumor cell lines in colony formation assays was also observed when BRCA1 was delivered via the RGDmodified Ad relative to Ad5 (data not shown). Taken together, our results suggest that in the breast and ovarian human tumor cell lines examined, the RGD-fiber knob modification results in an enhancement of functional BRCA1 expression up to B10-fold relative to delivery from Ad5 with the native fiber.
In summary, we have employed several different approaches to analyze the transductional efficacy mediated by a genetic modification of the Ad fiber knob 9 and find general agreement among the different methods of evaluation. The augmentation of gene expression mediated by AdRGD was observed in several in vitro (2-4) and in vivo model systems (Fig 5) . These RGDmodified Ad vectors may be useful for both BRCA1 structure-function studies and evaluation of simultaneous real-time vector distribution and BRCA1/mutantBRCA1 gene expression in an orthotopic model of ovarian cancer. Finally, tumor transduction rates of 5-10% were previously estimated in retroviral-mediated BRCA1 human gene therapy trials for advanced ovarian cancer, 47, 48 suggesting the need for additional gene therapy approaches. The transductional targeting of an AdRGD BRCA1 vector described herein, perhaps in combination with transcriptional targeting, 26, [74] [75] [76] may translate into a superior gene delivery vehicle to reintroduce functional BRCA1 into ovarian tumor cells.
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